CLAIMS

1. A method of treating a solid tumour in a subject, the method comprising the following steps

(i) delivering to the solid tumour a composition comprising an engineered ovine atadenovirus and a lipid; and

(ii) administering a prodrug to the subject,

wherein the engineered ovine atadenovirus comprises a promoter and a gene encoding an enzyme which converts the prodrug to a cytotoxic metabolite, the gene being under the control of the promoter.

2. A method as claimed in claim 1 in which the promoter is selectively active in a specific tissue.

3. A method as claimed in claim 1 or claim 2 in which the solid tumour is prostate cancer.

4. A method as claimed in claim 2 or claim 3 in which the specific tissue is prostate tissue.

5. A method as claimed in any one of claims 1 to 4 in which the promoter is a prostate specific membrane antigen promoter.

6. A method as claimed in any one of claims 1 to 5 in which the promoter is a probasin promoter.

7. A method as claimed in any one of claims 1 to 6 in which the ovine atadenovirus further comprises a transcriptional enhancer element.

8. A method as claimed in claim 7 in which the transcriptional enhancer element is from the prostate specific membrane antigen gene.

9. A method as claimed in any one of claims 1 to 8 in which the enzyme and the prodrug are an enzyme/prodrug combination selected from the group consisting of thymidine kinase/ganciclovir, thymidine kinase/acyclovir, bacterial cytosine deaminase /5-flurocytosine, human cytochrome P450/cyclophosphamide or ifosfamide, thymidine phosphorylase/5'-deoxy-5-flurouridine, cytosine kinase/cytosine arabinoside, *E. coli* GPT/ 6-thioxanthine, *E. coli* nitroreductase/5(-aziridine-1-yl)-2,4-dinitrobenzamide, and bacterial purine nucleoside phosphorylase/6-methylpurine-2-deoxyriboside or fludarabine.

10. A method as claimed in any one of claims 1 to 8 in which the enzyme is a purine nucleoside phosphorylase (PNP)and the prodrug is a purine prodrug which is converted by PNP to a toxic purine metabolite.

11. A method as claimed in claim 10 in which the prodrug is 6-methyl purine-2-deoxyriboside (6MPDR) or fludarabine.

12. A method as claimed in any one of claims 1 to 11 in which the lipid is a cationic lipid.

13. A method as claimed in any one of claims 1 to 12 in which the lipid is CSO87 having the formula :



14. A method as claimed in any one of claims 1 to 12 which the lipid is CSO60 having the formula:



15. A method as claimed in any one of claims 1 to 6 in which the engineered ovine atadenovirus is selected from the group consisting of OAdV220, OAdV223 and OAdV623.

16. A composition comprising

(i) an engineered ovine atadenovirus; and

(ii) a lipid,

wherein the engineered ovine atadenovirus comprises a promoter and a gene encoding an enzyme which converts a prodrug to a cytotoxic metabolite, the gene being under the control of the promoter.

17. A composition as claimed in claim 16 in which the promoter is selectively active in a specific tissue.

18. A composition as claimed in claim 16 or claim 17 in which the promoter is a prostate specific membrane antigen promoter.

19. A composition as claimed in any one of claims 16 to 18 in which the promoter is a probasin promoter.

20. A composition as claimed in any one of claims 16 to 19 in which the ovine atadenovirus further comprises a transcriptional enhancer element.

21. A composition as claimed in claim 20 in which the transcriptional enhancer element is from the prostate specific membrane antigen gene.

22. A composition as claimed in any one of claims 16 to 21 in which the enzyme and the prodrug are an enzyme/prodrug combination selected from the group consisting of thymidine kinase/ganciclovir, thymidine kinase/acyclovir, bacterial cytosine deaminase /5-flurocytosine, human cytochrome P450/cyclophosphamide or ifosfamide, thymidine phosphorylase/5'-deoxy-5-flurouridine, cytosine kinase/cytosine arabinoside, *E. coli* GPT/ 6-thioxanthine, *E. coli* nitroreductase/5(-aziridine-1-yl)-2,4-dinitrobenzamide, and bacterial purine nucleoside phosphorylase/6-methylpurine-2-deoxyriboside or fludarabine.

23. A composition as claimed in any one of claims 16 to 21 in which the enzyme is a purine nucleoside phosphorylase (PNP) and the prodrug is a purine prodrug which is converted by PNP to a toxic purine metabolite.

24. A composition as claimed in claim 23 in which the prodrug is 6-methyl purine-2-deoxyriboside (6MPDR) or fludarabine.

25. A composition as claimed in any one of claims 16 to 24 in which the lipid is a cationic lipid.

26. A composition as claimed in any one of claims 16 to 25 in which the lipid is CSO87 having the formula :



27. A composition as claimed in any one of claims 16 to 25 in which the lipid is CSO60 having the formula:



28. A composition as claimed in any one of claims 16 to 27 in which the engineered ovine atadenovirus is selected from the group consisting of OAdV220, OAdV223 and OAdV623.